Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Agios Pharma (DE:8AP)
FRANKFURT:8AP
Holding DE:8AP?
Track your performance easily
Earnings Data
Report Date
Feb 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-€1.62Last Year’s EPS
-€1.64Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2024
|% Change Since: -26.51%
|Next Earnings Date:Feb 13, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with significant milestone achievements, strong financial positioning, and promising advancements in clinical trials. However, challenges remain, particularly in pediatric PK deficiency and the sickle cell community. Overall, Agios appears well-positioned for future growth and product launches.Company Guidance
During the third quarter 2024 earnings call for Agios Pharmaceuticals (AGIO), the company provided detailed guidance on its financial and strategic outlook. Agios reported receiving $1.1 billion in milestone payments following the FDA approval of vorasidenib, contributing to a robust cash position of approximately $1.7 billion. This strong financial footing supports the planned launches of mitapivat in thalassemia in 2025 and in sickle cell disease in 2026. The company also highlighted the completion of enrollment for the Phase III RISE UP study in sickle cell disease, with primary endpoints focused on hemoglobin response and the annualized rate of sickle cell pain crises. Additionally, Agios emphasized its commercial strategy, targeting about 65% of the adult thalassemia patient population for its initial launch focus in the U.S. The company expressed confidence in its ongoing clinical programs, including the Phase IIb study of tebapivat in lower-risk myelodysplastic syndrome (MDS), which aims to address anemia in this patient population.Strong Cash Position and Milestone Payments
Agios received $1.1 billion in milestone payments following FDA approval of vorasidenib, enhancing the company's cash base to approximately $1.7 billion.
Positive Phase III Data and Advancements
Agios reported positive data in Phase III programs for mitapivat in PKD and thalassemia, and completed enrollment in the Phase III RISE UP sickle cell disease study.
Orphan Drug Designation for Tebapivat
The FDA granted orphan drug designation to tebapivat for the treatment of myelodysplastic syndromes, supporting Agios' potential in this market.
Commercial Preparation for Thalassemia Launch
Agios is actively preparing for a potential U.S. launch of PYRUKYND in thalassemia in 2025, targeting approximately 65% of the adult thalassemia patient population.
Increased Net Revenue from PYRUKYND
Third quarter 2024 net PYRUKYND revenue was $9 million, marking a 22% increase compared to the third quarter of 2023.
---
DE:8AP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DE:8AP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | €43.00 | €42.00 | -2.33% |
| Aug 01, 2024 | €43.00 | €40.20 | -6.51% |
| May 02, 2024 | €30.60 | €31.40 | +2.61% |
| Feb 15, 2024 | €23.20 | €23.80 | +2.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Agios Pharma (DE:8AP) report earnings?
Agios Pharma (DE:8AP) is schdueled to report earning on Feb 13, 2025, TBA Not Confirmed.
What is Agios Pharma (DE:8AP) earnings time?
Agios Pharma (DE:8AP) earnings time is at Feb 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Agios Pharma stock?
The P/E ratio of Agios Pharma is 2.8.
What is DE:8AP EPS forecast?
DE:8AP EPS forecast for the fiscal quarter 2024 (Q4) is -€1.62.
---